March 30, 2016

PaxVax Named Best Early-Stage Company at Vaccine Industry Excellence (ViE) Awards

Washington, D.C. and Redwood City, Calif. – March 30, 2016 – PaxVax Inc., a fully integrated specialty vaccine company committed to developing and commercializing innovative vaccines against infectious diseases, today announced that it was named Best Early-Stage Vaccine Biotech company at the 9th annual Vaccine Industry Excellence (ViE) Awards. Winners were announced at a ceremony held during the 16th annual World Vaccine Congress taking place in Washington, D.C., March 29-31.

“PaxVax is very proud of our rapid growth which has been fueled by our ability to attract leading investors, our success in commercializing vaccines like Vivotif that address compelling yet overlooked segments of the market, and the development progress of our robust pipeline which includes a late-stage cholera vaccine and an early-stage candidate for zika,” said Nima Farzan, President and CEO of PaxVax. “We are honored to be named Best Early-Stage company by our colleagues in the vaccine industry and congratulate all of the individuals and organizations recognized in this year’s ViE awards.”

PaxVax has extensive research and development capabilities, a world-class manufacturing facility and an on-the-ground sales presence in the U.S. and across Europe. The company manufactures and markets Vivotif®, an FDA-approved typhoid vaccine which is currently licensed in 27 countries including the U.S. and major European markets. On December 15, 2015, the U.S. Food and Drug Administration (FDA) accepted for filing and priority review the Biologics License Application (BLA) for the company’s single-dose oral cholera vaccine, Vaxchora™. The FDA’s action date for the Vaxchora BLA is June 15, 2016.

Dr. Lisa Danzig, Vice President, Clinical Development and Medical Affairs at PaxVax will discuss Vivotif and Vaxchora in her presentation, “Progress and clinical efficacy with new oral vaccines against Cholera and Typhoid,” at the World Vaccine Congress on Thursday, March 31 at 12:00pm ET.

The ViE awards were conceived to identify and reward organizations and individuals who have demonstrated an unparalleled ability to succeed and to continually set standards of excellence and advocacy in the vaccine industry over the previous 12 months. The ViE Awards judging panel is composed of senior industry representatives from governmental organizations, academia, industry and affiliate member associations, and are chosen for their knowledge, objectivity and credibility. More than 500 nominations were received across 10 categories for the 2016 ViE Awards. For more information please visit:

About PaxVax

Founded in 2007, PaxVax is a fully integrated specialty vaccine company with a mission to develop, manufacture and commercialize innovative vaccines against infectious diseases in a socially responsible manner. By focusing on diseases where there is unmet need and committing to socially responsible operations, PaxVax has been able to successfully address the compelling, overlooked traveler market with commercial and late-stage vaccine candidates. The PaxVax portfolio includes a licensed vaccine for typhoid (Vivotif®), and vaccines at various stages of research and clinical development for cholera, anthrax, HIV, hepatitis A, adenovirus and zika. PaxVax is headquartered in Redwood City, California and maintains research and development and Good Manufacturing Practice (GMP) facilities in San Diego, California, USA, and Bern, Switzerland. More information is available at